Global Virus Filtration Market By Product (Consumables (Kits and Reagents and Others), Instruments (Filtration Systems and Chromatography Systems), Filtration Membranes and Services), by Technology (Ultrafiltration (UF), Microfiltration (MF), Nanofiltration (NF), Chromatography-Based Filtration and Electropositive Filtration), By Application (Biopharmaceuticals, Water Purification, Air Purification, Food and Beverage, Medical Devices and Gene Therapy), By Application (Biopharmaceuticals, Water Purification, Air Purification, Food and Beverage, Medical Devices, and Gene Therapy), By End Use (Biopharmaceutical Manufacturers, Contract Manufacturing Organizations (CMOs), Research Laboratories, Hospitals and Healthcare Centers, Medical device companies and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

Global Virus Filtration Market size is expected to be worth around US$ 7.81 billion by 2034 from US$ 3.79 billion in 2024, growing at a CAGR of 7.5% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 41.4% share with a revenue of US$ 1.57 Billion.

The virus filtration market is driven by the increasing demand for clean and safe water, the rising prevalence of infectious diseases, and stringent regulations regarding water treatment and air purification. According to WHO, In 2021, chronic diseases were responsible for at least 43 million deaths, accounting for 75% of all deaths unrelated to pandemics worldwide.

Among these, 18 million people died from an NCD before reaching the age of 70, with 82% of these premature deaths occurring in low- and middle-income countries. Overall, 73% of all NCD-related deaths happen in these regions. Cardiovascular diseases are the leading cause of NCD deaths, with at least 19 million fatalities in 2021, followed by cancers (10 million), chronic respiratory diseases (4 million), and diabetes (over 2 million, including kidney disease deaths linked to diabetes). Together, these four groups of diseases account for 80% of all premature NCD deaths.

Key risk factors contributing to NCD-related deaths include tobacco use, physical inactivity, excessive alcohol consumption, unhealthy diets, and air pollution. Effective responses to NCDs involve detection, screening, treatment, and palliative care. It focuses on preventing viral contamination in a range of applications, including water treatment, pharmaceuticals, biotechnology, and food & beverage industries. The growing concerns about health risks associated with waterborne and airborne viruses have led to the adoption of filtration technologies that effectively remove viruses from fluids and gases.

Key market drivers include advancements in filtration technologies, such as membrane filtration and nanotechnology, which offer high efficiency in viral removal. The pharmaceutical and biotechnology sectors are particularly significant, with virus filtration used extensively in the production of vaccines, biologics, and other life-saving medicines. Additionally, the COVID-19 pandemic has heightened the demand for virus filtration solutions, further fueling market growth. Leading players in the market are innovating to offer more effective and sustainable filtration systems.

Key Takeaways

• In 2024, the market for Virus Filtration generated a revenue of US$ 79 billion, with a CAGR of 7.5%, and is expected to reach US$ 7.81 billion by the year 2033.
• The product and services segment is divided into Consumables (Kits and Reagents and Others), Instruments (Filtration Systems and Chromatography Systems), Filtration Membranes and Services, with Consumables taking the lead in 2023 with a market share of 38.6%.
• By Technology, the market is bifurcated into Ultrafiltration (UF), Microfiltration (MF), Nanofiltration (NF), Chromatography-Based Filtration and Electropositive Filtration, with Ultrafiltration (UF) leading the market with 35.5% of market share.
• Furthermore, concerning the Application segment, the market is segregated into Biopharmaceuticals, Water Purification, Air Purification, Food and Beverage, Medical Devices, and Gene Therapy. The Biopharmaceuticals sector stands out as the dominant segment, holding the largest revenue share of 37.2% in the Virus Filtration market.
• Considering end user segment, the market is bifurcated into Biopharmaceutical Manufacturers, Contract Manufacturing Organizations (CMOs), Research Laboratories, Hospitals and Healthcare Centers, Medical device companies and Others. Biopharmaceutical Manufacturers dominated the market with 34.0% market share.
• North America led the market by securing a market share of 41.4% in 2023.

Product Analysis

The Consumables segment leads the market with 38.6% market share with the Kits and Reagents segment dominating, driven by the increasing use of consumable materials in laboratories and manufacturing facilities for virus filtration in the biotech and healthcare industries. However, instruments and services are smaller but growing segments, with instruments being essential for monitoring and controlling filtration systems.

Services, such as installation, maintenance, and support, are gaining traction as industries demand more tailored solutions for their filtration needs. Filtration membranes also dominate the market due to their critical role in effectively removing viruses in applications like pharmaceutical production, biotechnology, and water treatment. Membrane filtration offers high efficiency and reliability, making it the preferred solution for viral removal.

Technology Analysis

In the Virus Filtration Market, the technology segmentation includes Ultrafiltration (UF), Microfiltration (MF), Nanofiltration (NF), Chromatography-Based Filtration, and Electropositive Filtration. Among these, Ultrafiltration (UF) is the dominant segment with 35.5% market share due to its high efficiency in separating viruses from liquids, making it ideal for applications in water treatment, pharmaceutical, and biotechnology industries. UF offers superior pore size and membrane performance, ensuring effective viral filtration while maintaining high throughput.

In March 2025, DuPont Water Solutions introduced WAVE PRO, an advanced online modeling tool designed for a range of ultrafiltration (UF) water treatment applications, including drinking water, industrial utility water, wastewater, and seawater desalination.

Microfiltration (MF) follows closely, particularly in applications where larger virus particles need to be removed. It is commonly used in industries like food and beverage processing. Nanofiltration (NF) also holds a strong position, providing a higher filtration capacity for smaller viruses and contaminants.

Application Analysis

In the Virus Filtration Market, the segmentation by application includes biopharmaceuticals, water purification, air purification, food and beverage, medical devices, and gene therapy. Among these, biopharmaceuticals dominated the market with 37.2% market share, driven by the increasing need for viral safety in the production of vaccines, biologics, and other therapeutic products. Virus filtration is crucial in ensuring the safety and sterility of biologics, making this sector the largest and fastest-growing application.

Water purification follows closely due to the rising demand for clean water and the growing concern about waterborne viral diseases. Air purification is also a significant segment, with heightened focus on air filtration systems, particularly after the COVID-19 pandemic. Many market players are launching products in this segment which is resulting in market growth.

For instance, in October 2024, Asahi Kasei Medical has introduced the Planova FG1, a virus removal filter with enhanced flux capabilities, specifically designed for the production of biotherapeutics. The bioprocess division of Asahi Kasei Medical includes Planova virus removal filters and related equipment used in the manufacturing of biotherapeutic products, such as biopharmaceuticals and plasma derivatives. It also offers biosafety testing services and biopharmaceutical CDMO operations. This division is a key driver of future growth within the Asahi Kasei Group.

End User Analysis

Biopharmaceutical manufacturers dominated the market with 34.0% market share due to the critical need for virus filtration in the production of vaccines, biologics, and therapeutic proteins. Strict regulatory requirements and the need for viral safety in drug development make this sector the largest consumer of virus filtration technologies.

Contract Manufacturing Organizations (CMOs) also hold a significant share as they provide outsourced manufacturing services to pharmaceutical companies, which require virus filtration solutions to ensure the purity of their products. In May 2024, Asahi Kasei Medical has finished constructing its third assembly plant for Planova virus removal filters in Nobeoka, Miyazaki, Japan, and held a completion ceremony on May 24.

Key Market Segments

Product

• Consumables
  • Kits and Reagents
  • Others
• Instruments
  • Filtration Systems
  • Chromatography Systems
• Filtration Membranes
• Services

Technology

• Ultrafiltration (UF)
• Microfiltration (MF)
• Nanofiltration (NF)
• Chromatography-Based Filtration
• Electropositive Filtration

Application

• Biopharmaceuticals
• Water Purification
• Air Purification
• Food and Beverage
• Medical Devices
• Gene Therapy

End User

• Biopharmaceutical Manufacturers
• Contract Manufacturing Organizations (CMOs)
• Research Laboratories
• Hospitals and Healthcare Centers
• Medical device companies
• Others

Drivers

Rising Concerns About Health and Safety

One of the major drivers of the virus filtration market is the growing global concern about health and safety, particularly regarding viral contamination in water, air, and biopharmaceutical products. The increasing prevalence of infectious diseases and viruses, such as COVID-19, has heightened the need for effective virus filtration systems.

Regulatory standards, particularly in the pharmaceutical and biotechnology sectors, also mandate virus filtration in the production of vaccines, biologics, and other medical products, further driving demand. As a result, industries are adopting advanced filtration technologies to ensure the safety and sterility of products, fueling the growth of the virus filtration market.

In May 2023, leveraging its leadership in biopharma filtration technology, 3M announced an investment of $146 million to enhance its capabilities and support the rapidly growing biotech manufacturing sector, which is advancing breakthrough therapies for patients.

The investment will fund facility and equipment upgrades, as well as the creation of 60 full-time positions at 3M’s manufacturing facilities in Europe. This investment aims to accelerate the development and delivery of critical filtration equipment for bioprocessing, biological, and small molecule pharmaceutical manufacturing applications.

Restraints

High Initial Costs

A significant restraint in the virus filtration market is the high initial cost of filtration systems, particularly advanced technologies like ultrafiltration and nanofiltration. The cost of installation, maintenance, and ongoing operational expenses can be prohibitive for smaller companies or industries operating on a budget. These high capital expenditures limit the adoption of virus filtration solutions, especially in developing regions or industries with budget constraints.

For instance, Sterile Membrane Filters typically range from USD 50 to USD 320 per membrane. While this may seem modest, the overall costs can escalate quickly when considering large-scale operations. Moreover, advanced filtration systems can cost between USD 50,000 and USD 210,000. This includes installation and setup, which are necessary for compliance with industry regulations.

Opportunities

Technological Advancements

The increasing pace of technological advancements presents a significant opportunity in the virus filtration market. New innovations in filtration technologies, such as electropositive filtration and chromatography-based filtration, offer higher efficiency, lower operational costs, and more sustainable solutions.

These advancements allow industries to improve viral removal rates while reducing energy consumption and overall operational costs. The growing interest in personalized medicine, gene therapy, and biologics presents additional opportunities for virus filtration systems that can meet the stringent demands of these advanced therapies.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors significantly influence the Virus Filtration Market. Economic downturns or slowdowns can limit investments in advanced filtration technologies, especially in industries with tight budgets like small to medium-sized enterprises (SMEs). In such scenarios, businesses may prioritize cost-cutting measures, reducing expenditure on high-end virus filtration systems, thus impacting market growth.

Geopolitical factors, including trade tensions, regulatory changes, and global health crises (e.g., COVID-19), can create supply chain disruptions and affect the availability of raw materials, such as filtration membranes. These challenges can lead to price fluctuations and delays in product availability, particularly in regions highly dependent on imports.

On the positive side, global health emergencies often accelerate the demand for virus filtration solutions, especially in the pharmaceutical and healthcare sectors. Heightened awareness of viral transmission during pandemics can increase investments in contamination control systems, driving market growth. Thus, while geopolitical and macroeconomic factors can pose challenges, they also offer opportunities, especially during global health crises.

Latest Trends

Increasing Demand for Single-Use Systems

A notable trend in the virus filtration market is the growing preference for single-use filtration systems, particularly in the biopharmaceutical industry. Single-use technologies offer multiple benefits, including reduced risk of cross-contamination, lower operational costs, and enhanced flexibility in production. As the biopharmaceutical industry focuses on more efficient and cost-effective manufacturing processes, single-use systems are gaining traction.

This trend is also driven by the rise in demand for biologics, vaccines, and gene therapies, which require highly sterile and flexible production environments. Single-use systems help streamline operations while meeting strict regulatory requirements, making them a popular choice in the market.

Regional Analysis

North America is leading the Virus Filtration Market

North America is leading the Virus Filtration Market due to a combination of strong healthcare infrastructure, stringent regulatory standards, and high demand for advanced filtration technologies in key industries such as pharmaceuticals, biotechnology, and healthcare. The region’s biopharmaceutical sector, in particular, drives market growth, as strict regulatory requirements for virus-free products in vaccine production, biologics, and therapeutic protein manufacturing fuel the need for effective filtration solutions.

For example, the U.S. Food and Drug Administration (FDA) mandates virus filtration for the production of biologics, creating a substantial market for filtration technologies. The region also benefits from ongoing investments in research and development, particularly in biotechnology and gene therapy, further increasing demand for high-quality virus filtration systems.

Additionally, the COVID-19 pandemic heightened the need for advanced air and water filtration systems, further bolstering North America’s market position. Major players like Merck, Pall Corporation, and Thermo Fisher Scientific are also headquartered in North America, contributing to the region’s leadership.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

Key players in the Virus Filtration market includes Merck KGaA, Pall Corporation (Danaher Corporation), Thermo Fisher Scientific, Asahi Kasei Medical Co., Ltd., MilliporeSigma (Merck Group), GE Healthcare Life Sciences, Bio-Rad Laboratories, Inc., Danaher Corporation, Eppendorf AG, Sartorius AG, Repligen Corporation, 3M Purification, Koch Membrane Systems, Inc., Wright Medical Group N.V., Lonza Group, and other key players.

Merck KGaA’s innovation in filtration solutions, such as its MilliporeSigma brand, is driving its strong presence in the market, particularly in research and development settings. Pall Corporation, now a part of Danaher Corporation, is another leader in the virus filtration market, known for its advanced filtration systems used in pharmaceutical, biotechnology, and water treatment industries.

Pall Corporation’s Virapur and Ultipor product lines offer highly effective solutions for viral clearance and ensuring the safety of biological products, contributing to its market dominance. Thermo Fisher Scientific provides a comprehensive range of virus filtration products, including membranes, filters, and services, aimed at the biotechnology and pharmaceutical sectors.

Top Key Players

• Merck KGaA
• Pall Corporation (Danaher Corporation)
• Thermo Fisher Scientific
• Asahi Kasei Medical Co., Ltd.
• MilliporeSigma (Merck Group)
• GE Healthcare Life Sciences
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Eppendorf AG
• Sartorius AG
• Repligen Corporation
• 3M Purification
• Koch Membrane Systems, Inc.
• Wright Medical Group N.V.
• Lonza Group
• Other key players

Recent Developments

• In October 2024, Asahi Kasei Medical introduced the Planova FG1, an advanced virus removal filter designed with a higher flux for biotherapeutic manufacturing. Asahi Kasei Medical’s bioprocess division includes Planova virus removal filters and equipment utilized in the production of biotherapeutic products like biopharmaceuticals and plasma derivatives, along with biosafety testing services and biopharmaceutical CDMO operations.
• In December 2023, TeraPore Technologies, a leader in nanofiltration membranes, has officially launched its flagship IsoBlock VF product line for the removal of parvovirus from biopharmaceuticals. During evaluations at several customer sites across various novel antibody constructs, IsoBlock VF has shown reliable and consistent performance.
• In July 2021, Asahi Kasei Medical announced plans to increase the production capacity of hydrophilic PVDF (polyvinylidene fluoride) hollow-fiber membranes for Planova BioEX filters at its spinning plant in Oita, Japan. The global COVID-19 pandemic has driven a surge in demand for Planova filters, which are crucial for the development and mass production of anti-coronavirus agents.

Report Scope